236 related articles for article (PubMed ID: 23751135)
1. Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T.
Vos EK; Litjens GJ; Kobus T; Hambrock T; Hulsbergen-van de Kaa CA; Barentsz JO; Huisman HJ; Scheenen TW
Eur Urol; 2013 Sep; 64(3):448-55. PubMed ID: 23751135
[TBL] [Abstract][Full Text] [Related]
2. Dynamic contrast-enhanced (DCE) MR imaging: the role of qualitative and quantitative parameters for evaluating prostate tumors stratified by Gleason score and PI-RADS v2.
Afshari Mirak S; Mohammadian Bajgiran A; Sung K; Asvadi NH; Markovic D; Felker ER; Lu D; Sisk A; Reiter RE; Raman SS
Abdom Radiol (NY); 2020 Jul; 45(7):2225-2234. PubMed ID: 31549211
[TBL] [Abstract][Full Text] [Related]
3. Multiparametric Magnetic Resonance Imaging for Discriminating Low-Grade From High-Grade Prostate Cancer.
Vos EK; Kobus T; Litjens GJ; Hambrock T; Hulsbergen-van de Kaa CA; Barentsz JO; Maas MC; Scheenen TW
Invest Radiol; 2015 Aug; 50(8):490-7. PubMed ID: 25867656
[TBL] [Abstract][Full Text] [Related]
4. A direct comparison of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer detection and prediction of aggressiveness.
Baur ADJ; Schwabe J; Rogasch J; Maxeiner A; Penzkofer T; Stephan C; Rudl M; Hamm B; Jung EM; Fischer T
Eur Radiol; 2018 May; 28(5):1949-1960. PubMed ID: 29238867
[TBL] [Abstract][Full Text] [Related]
5. DCE-MRI of the prostate using shutter-speed vs. Tofts model for tumor characterization and assessment of aggressiveness.
Hectors SJ; Besa C; Wagner M; Jajamovich GH; Haines GK; Lewis S; Tewari A; Rastinehad A; Huang W; Taouli B
J Magn Reson Imaging; 2017 Sep; 46(3):837-849. PubMed ID: 28092414
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Dispersion MRI for Improved Prostate Cancer Diagnosis in a Multicenter Study.
Turco S; Lavini C; Heijmink S; Barentsz J; Wijkstra H; Mischi M
AJR Am J Roentgenol; 2018 Nov; 211(5):W242-W251. PubMed ID: 30346837
[TBL] [Abstract][Full Text] [Related]
7. Dynamic contrast-enhanced case-control analysis in 3T MRI of prostate cancer can help to characterize tumor aggressiveness.
Sanz-Requena R; Martí-Bonmatí L; Pérez-Martínez R; García-Martí G
Eur J Radiol; 2016 Nov; 85(11):2119-2126. PubMed ID: 27776667
[TBL] [Abstract][Full Text] [Related]
8. Patient-specific pharmacokinetic parameter estimation on dynamic contrast-enhanced MRI of prostate: Preliminary evaluation of a novel AIF-free estimation method.
Ginsburg SB; Taimen P; Merisaari H; Vainio P; Boström PJ; Aronen HJ; Jambor I; Madabhushi A
J Magn Reson Imaging; 2016 Dec; 44(6):1405-1414. PubMed ID: 27285161
[TBL] [Abstract][Full Text] [Related]
9. Quantitative diffusion-weighted imaging and dynamic contrast-enhanced characterization of the index lesion with multiparametric MRI in prostate cancer patients.
Yuan Q; Costa DN; Sénégas J; Xi Y; Wiethoff AJ; Rofsky NM; Roehrborn C; Lenkinski RE; Pedrosa I
J Magn Reson Imaging; 2017 Mar; 45(3):908-916. PubMed ID: 27442039
[TBL] [Abstract][Full Text] [Related]
10. Comparing diagnostic accuracy of luminal water imaging with diffusion-weighted and dynamic contrast-enhanced MRI in prostate cancer: A quantitative MRI study.
Sabouri S; Chang SD; Goldenberg SL; Savdie R; Jones EC; Black PC; Fazli L; Kozlowski P
NMR Biomed; 2019 Feb; 32(2):e4048. PubMed ID: 30575145
[TBL] [Abstract][Full Text] [Related]
11. Quantitative pharmacokinetic analysis of prostate cancer DCE-MRI at 3T: comparison of two arterial input functions on cancer detection with digitized whole mount histopathological validation.
Fennessy FM; Fedorov A; Penzkofer T; Kim KW; Hirsch MS; Vangel MG; Masry P; Flood TA; Chang MC; Tempany CM; Mulkern RV; Gupta SN
Magn Reson Imaging; 2015 Sep; 33(7):886-94. PubMed ID: 25683515
[TBL] [Abstract][Full Text] [Related]
12. Performance of Ultrafast DCE-MRI for Diagnosis of Prostate Cancer.
Chatterjee A; He D; Fan X; Wang S; Szasz T; Yousuf A; Pineda F; Antic T; Mathew M; Karczmar GS; Oto A
Acad Radiol; 2018 Mar; 25(3):349-358. PubMed ID: 29167070
[TBL] [Abstract][Full Text] [Related]
13. Dynamic contrast enhanced MRI of the prostate: comparison of gadobutrol and Gd-DTPA.
Durmus T; Vollnberg B; Schwenke C; Kilic E; Huppertz A; Taupitz M; Franiel T
Rofo; 2013 Sep; 185(9):862-8. PubMed ID: 23888476
[TBL] [Abstract][Full Text] [Related]
14. The Assessment of Prostate Cancer Aggressiveness Using a Combination of Quantitative Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
Zhu G; Luo J; Ouyang Z; Cheng Z; Deng Y; Guan Y; Du G; Zhao F
Cancer Manag Res; 2021; 13():5287-5295. PubMed ID: 34239327
[TBL] [Abstract][Full Text] [Related]
15. Contrast-enhanced dynamic and diffusion-weighted MR imaging at 3.0T to assess aggressiveness of bladder cancer.
Zhou G; Chen X; Zhang J; Zhu J; Zong G; Wang Z
Eur J Radiol; 2014 Nov; 83(11):2013-8. PubMed ID: 25213829
[TBL] [Abstract][Full Text] [Related]
16. T2-weighted hypointense lesions within prostate gland: differential diagnosis using wash-in rate parameter on the basis of dynamic contrast-enhanced magnetic resonance imaging--hystopatology correlations.
Valentini AL; Gui B; Cina A; Pinto F; Totaro A; Pierconti F; Bassi PF; Bonomo L
Eur J Radiol; 2012 Nov; 81(11):3090-5. PubMed ID: 22727777
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
18. Preoperative histogram parameters of dynamic contrast-enhanced MRI as a potential imaging biomarker for assessing the expression of Ki-67 in prostate cancer.
Zhang Y; Li Z; Gao C; Shen J; Chen M; Liu Y; Cao Z; Pang P; Cui F; Xu M
Cancer Med; 2021 Jul; 10(13):4240-4249. PubMed ID: 34117733
[TBL] [Abstract][Full Text] [Related]
19. Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy?
Donati OF; Jung SI; Vargas HA; Gultekin DH; Zheng J; Moskowitz CS; Hricak H; Zelefsky MJ; Akin O
Radiology; 2013 Aug; 268(2):440-50. PubMed ID: 23481164
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Diffusion Kurtosis Imaging Versus Standard Diffusion Imaging for Detection and Grading of Peripheral Zone Prostate Cancer.
Roethke MC; Kuder TA; Kuru TH; Fenchel M; Hadaschik BA; Laun FB; Schlemmer HP; Stieltjes B
Invest Radiol; 2015 Aug; 50(8):483-9. PubMed ID: 25867657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
